Acorda Therapeutics (Acorda Therapeutics) Days Payable : 219.00 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Days Payable?

Acorda Therapeutics's average Accounts Payable for the three months ended in Dec. 2023 was $13.4 Mil. Acorda Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $5.6 Mil. Hence, Acorda Therapeutics's Days Payable for the three months ended in Dec. 2023 was 219.00.

The historical rank and industry rank for Acorda Therapeutics's Days Payable or its related term are showing as below:

ACORQ' s Days Payable Range Over the Past 10 Years
Min: 73.37 Med: 122.7 Max: 399.08
Current: 205.31

During the past 13 years, Acorda Therapeutics's highest Days Payable was 399.08. The lowest was 73.37. And the median was 122.70.

ACORQ's Days Payable is ranked better than
83.15% of 979 companies
in the Drug Manufacturers industry
Industry Median: 86.3 vs ACORQ: 205.31

Acorda Therapeutics's Days Payable increased from Dec. 2022 (216.04) to Dec. 2023 (219.00). It may suggest that Acorda Therapeutics delayed paying its suppliers.

Acorda Therapeutics Days Payable Historical Data

The historical data trend for Acorda Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Days Payable Chart

Acorda Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

399.08

220.09

113.62

131.78

294.08

Acorda Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															216.04	182.57	89.75	208.86	219.00

Competitive Comparison of Acorda Therapeutics's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acorda Therapeutics's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Days Payable falls into.

Acorda Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Acorda Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (10.087	+	14.54)	/	2 )	/	15.283	*	365
=	12.3135					/	15.283	*	365
=	294.08

Acorda Therapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (12.33	+	14.54)	/	2 )	/	5.598	*	365 / 4
=	13.435					/	5.598	*	365 / 4
=	219.00

Acorda Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Acorda Therapeutics (Acorda Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965

Website

https://www.acorda.com

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Executives

Thomas M. Burns	director	2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen	officer: CEO and President	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser	officer: Chief Financial Officer	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff	officer: General Counsel	11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem	officer: Chief Commercial Officer	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales	officer: Interim PAO & PFO	420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman	officer: Exec V Pres, Gen Cnsl & Sec	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella	officer: Exec. VP-Commercial Dvlpmnt	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence	officer: Chief Financial Officer	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp	10 percent owner	152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank	officer: Chief Medical Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc.	10 percent owner	152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich	10 percent owner	C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123